Russia's RDIF Agreed On Producing 100Mln Doses Of Sputnik V Coronavirus Vaccine In India
Mohammad Ali (@ChaudhryMAli88) Published November 27, 2020 | 11:10 AM
MOSCOW (UrduPoint News / Sputnik - 27th November, 2020) The Russian Direct Investment Fund (RDIF) announced on Friday that it reached an agreement with India's pharmaceutical company Hetero on producing over 100 million doses of Russia's coronavirus vaccine Sputnik V per year in India.
"RDIF ... and Hetero, one of India's leading generic pharmaceutical companies (through its biologics arm "Hetero Biopharma") have agreed to produce in India over 100 million doses per year of the world's first registered vaccine against the novel coronavirus infection - Sputnik V," RDIF said in a press release, published in the Twitter account of the vaccine.
Production is expected to start in the beginning of 2021.
"I am confident that Sputnik V should become an integral part of the national vaccine portfolio of every country willing to protect its population from the coronavirus. Thanks to our cooperation with Hetero, we will be able to significantly increase production capacity and provide people of India with an efficient solution in this challenging period of the pandemic," RDIF CEO Kirill Dmitriev said, as quoted in the press release.
Hetero Labs Limited Director for International Marketing B. Murali Krishna Reddy noted that the company was pleased to cooperate with RDIF as a manufacturing partner for the "most anticipated" vaccine.
"While we look forward to the clinical trial results in India, we believe that manufacturing the product locally is crucial to enable swift access to patients. This collaboration is another step towards our commitment in the battle against Covid-19 and realizing the objective of 'Make-in-India' campaign," Reddy said, as quoted in the press release.
In August, Sputnik V, developed by the Gamaleya research institute and produced in cooperation with RDIF, became the world's first registered vaccine against COVID-19. According to the results of the second interim analysis of the clinical trials data, the vaccine has proven to be 91.4 percent effective 28 days after the injection of the first dose and 95 percent effective 42 days after the injection of the first dose.
Related Topics
Recent Stories
Currency Rate In Pakistan - Dollar, Euro, Pound, Riyal Rates On 27 April 2024
Today Gold Rate in Pakistan 27 April 2024
HEC reviews curricula for environmental sciences degree programme
ICC Asia looking forward to an action-packed Asia Cricket Week
Yuvraj Singh named ICC Men’s T20 World Cup 2024 Ambassador
Greece hands Olympic flame to 2024 Paris Games hosts
Two Kyiv hospitals evacuating over feared Russian strikes
World must act on neurotech revolution, say experts
Charles & Catherine's cancer diagnoses
Champions Alcaraz and Sabalenka through in Madrid Open
King Charles to resume some public duties during cancer treatment: palace
US defense chief announces $6 bn in security aid for Ukraine
More Stories From World
-
Haliburton hits winner as Pacers hold off Bucks in overtime, Mavs thump Clippers
6 minutes ago -
'Everyone sits out': Yangon parks offer heatwave relief
6 minutes ago -
6,000 French police to welcome Olympic torch amid bonus boost
16 minutes ago -
Golf: LPGA LA Championship scores
26 minutes ago -
Tennis: ATP/WTA Madrid Open results - collated
56 minutes ago -
PGA Zurich Classic of New Orleans scores
56 minutes ago
-
Sudanese filmmakers shine light on war's 'silent problems'
56 minutes ago -
NFL will allow players to wear Guardian Cap helmets in games
8 hours ago -
Football: German Bundesliga table
8 hours ago -
Football: Italian Serie A result
8 hours ago -
Football: German Bundesliga results
8 hours ago -
US troops to leave Chad in second African state withdrawal
8 hours ago